Scarica l'app Stockscreener
27.60
9.06%
-2.75
Dopo l'orario di chiusura:
27.64
0.04
+0.14%
Precedente Chiudi:
$30.35
Aprire:
$29.4
Volume 24 ore:
16,817
Relative Volume:
2.43
Capitalizzazione di mercato:
$2.57B
Reddito:
$136.33M
Utile/perdita netta:
$-56.34M
Rapporto P/E:
-36.78
EPS:
-0.7504
Flusso di cassa netto:
$-18.87M
1 W Prestazione:
-11.85%
1M Prestazione:
-19.53%
6M Prestazione:
-12.41%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$27.50
$29.40
Intervallo di 1 settimana:
$27.50
$31.20
Portata 52W:
$17.09
$48.45
Ascentage Pharma Group International Adr Stock (AAPG) Company Profile
Nome
Ascentage Pharma Group International Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta AAPG con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AAPG
Ascentage Pharma Group International Adr
|
27.60 | 2.82B | 136.33M | -56.34M | -18.87M | -0.7504 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ascentage Pharma Group International Adr Stock (AAPG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-04 | Iniziato | Oppenheimer | Outperform |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-11-10 | Iniziato | BTIG Research | Buy |
| 2025-11-05 | Iniziato | Piper Sandler | Overweight |
| 2025-03-27 | Iniziato | JP Morgan | Overweight |
Ascentage Pharma Group International Adr Borsa (AAPG) Ultime notizie
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap DownHere's What Happened - MarketBeat
Ascentage Pharma showcases promising data for olverembatinib at ASH 2025 - MSN
Ascentage Pharma Showcases Promising Data for Olverembatinib at ASH 2025 - TipRanks
ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment - GlobeNewswire Inc.
Ascentage Pharma Unveils Promising Lisaftoclax Data at ASH 2025 - TipRanks
Cash per share of Ascentage Pharma Group International Unsponsored ADR – LSX:A40ZYR - TradingView
ETFs Investing in Ascentage Pharma Group International Unsponsored ADR Stocks - TradingView
Cash per share of Ascentage Pharma Group International Unsponsored ADR – LS:A40ZYR - TradingView
Ascentage Pharma to Highlight Key Data from ASH 2025 in Upcoming Webcast - TipRanks
Ascentage Pharma Announces New RSU and Share Option Grants - TipRanks
Analysts’ Top Healthcare Picks: Amgen (AMGN), Opus Genetics (IRD) - The Globe and Mail
Ascentage Pharma’s Olverembatinib Shows Promise in Rare GIST Treatment - TipRanks
Ascentage Pharma Group International (NASDAQ:AAPG) Now Covered by Analysts at Truist Financial - Defense World
Ascentage Pharma Group International ADR (AAPG) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Ascentage Pharma Group International ADR (AAPG) Stock Price Today | Live Chart & News - Traders Union
Ascentage Pharma Group International ADR (AAPG) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 12.2%Should You Sell? - MarketBeat
Ascentage Pharma to Engage Investors at December 2025 Conferences - TipRanks
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), NeurAxis, Inc. (NRXS) and Celcuity (CELC) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: AMN Healthcare Services (AMN) and Crispr Therapeutics AG (CRSP) - The Globe and Mail
Promising Potential of Ascentage Pharma’s Key Assets: Olverembatinib and Lisaftoclax Drive Buy Rating Amidst Risks - TipRanks
Free cash flow per share of Ascentage Pharma Group International Unsponsored ADR – SWB:36X0 - TradingView
Ascentage Pharma to Engage Investors at November Conferences - TipRanks
Centurion Acquisition Corp. (NASDAQ:ALFUW) Short Interest Down 57.1% in October - Defense World
Ascentage Pharma Group InternationalUnsponsored ADR (NASDAQ:AAPG) Short Interest Down 82.7% in October - MarketBeat
Zymeworks’ Promising FRa ADC Potential: Buy Rating Affirmed by Analyst - TipRanks
Revolution Medicines: Strong Buy Rating Driven by Innovative Oncology Advancements and Strategic Market Position - TipRanks
Promising Early-Stage Data and Competitive Positioning Support Buy Rating for Zymeworks’ ADC Platform - TipRanks
Allogene Therapeutics (ALLO) was downgraded to a Sell Rating at J.P. Morgan - The Globe and Mail
Ascentage Pharma Group International (NASDAQ:AAPG) Trading Up 3.5%Here's What Happened - MarketBeat
J.P. Morgan Reaffirms Their Buy Rating on Roivant Sciences (ROIV) - The Globe and Mail
Ascentage Pharma Engages Investors at October 2025 Conferences - TipRanks
Ascentage Pharma Group International (OTCMKTS:ASPHF) Short Interest Up 70.0% in September - Defense World
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 4.5%Here's What Happened - MarketBeat
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap UpStill a Buy? - MarketBeat
Here's Why Ascentage Pharma Group InternationalUnsponsored ADR (AAPG) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Ascentage Pharma to Engage with Investors at September Conferences - TipRanks
Ascentage Pharma Group International (NASDAQ:AAPG) Reaches New 52-Week High – Should You Buy? - Defense World
Ascentage Pharma Group International Adr Azioni (AAPG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):